Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Emergent Biosolutions

Emergent Biosolutions (NYSE: EBS) insider transactions

In the twelve months to 10 November 2026, executives and directors of Emergent Biosolutions reported 13 open-market sales of 111,709 shares ($986,093) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Emergent Biosolutions shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
7 October 2026DeGolyer Donald WDirectorOpen-market sale, 10b5-1 plan−17,800$7.09111,921Form 4
1 October 2026Williams Paul AnthonySVP, Products BusinessOpen-market sale, 10b5-1 plan−3,000$6.53156,098Form 4
1 July 2026Williams Paul AnthonySVP, Products BusinessOpen-market sale, 10b5-1 plan−3,000$8.40159,098Form 4
8 June 2026Lindahl Richard SEVP, Chief Financial OfficerShares withheld for tax−3,964$8.00374,083Form 4
8 June 2026Glessner ColeenEVP, Quality & Ethics, and CPLShares withheld for tax−2,018$8.00202,201Form 4
8 June 2026Williams Paul AnthonySVP, Products BusinessShares withheld for tax−694$8.00162,098Form 4
8 June 2026Hartzel WilliamSVP, BioservicesShares withheld for tax−1,741$8.00185,558Form 4
1 May 2026Dayal Sujata TyagiDirectorOpen-market sale, 10b5-1 plan−12,781$8.36101,543Form 4
1 May 2026Dayal Sujata TyagiDirectorOpen-market sale, 10b5-1 plan−980$8.94100,563Form 4
1 May 2026DeGolyer Donald WDirectorOpen-market sale, 10b5-1 plan−14,527$8.36130,675Form 4
1 May 2026DeGolyer Donald WDirectorOpen-market sale, 10b5-1 plan−954$8.96129,721Form 4
1 May 2026Zoon Kathryn CDirectorOpen-market sale, 10b5-1 plan−16,145$8.3680,998Form 4
1 May 2026Zoon Kathryn CDirectorOpen-market sale, 10b5-1 plan−1,057$8.9779,941Form 4
30 April 2026Fowler John D JRDirectorGrant or award+25,344—30,350Form 4
30 April 2026Katkin KeithDirectorGrant or award, 10b5-1 plan+25,344—111,775Form 4
30 April 2026Katkin KeithDirectorOpen-market sale, 10b5-1 plan−15,481$8.2896,294Form 4
30 April 2026Richard RonaldDirectorGrant or award+25,344—123,761Form 4
30 April 2026Harsanyi ZsoltChairmanGrant or award+25,344—149,076Form 4
30 April 2026White Marvin LDirectorGrant or award+25,344—113,839Form 4
30 April 2026Fowler Neal FranklinDirectorGrant or award+25,344—160,847Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Emergent Biosolutions page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.